Anna Jarząb, PhD

Anna Jarząb, PhD (Assistant Professor) – Group Leader

 

The Group of Proteomics and Immunoenzymatic Analysis

Laboratory of Medicinal Microbiology

 

Research interests:

Dr Anna Jarzab completed her PhD at the Institute of Immunology and Experimental Therapy of the Polish Academy of Science in Wroclaw, Poland in 2014. Under her PhD she was working on the anti-Shigella vaccine development. Next, in 2015 she joined the group of Prof. Bernhard Kuster at the Chair of Proteomics and Bioanalytics, Technical University of Munich, where she was working on the acquired drug resistance in cancer and thermal proteome profiling by proteomics. Now she works at the Institute of Immunology and Experimental Therapy of the Polish Academy of Science in Wroclaw.  In her research work she utilizes biochemical, immunological and enzymatic techniques, aided by cell culture and proteomics approaches to work on two main topics:

  • Anti-bacterial vaccine development

The lab focuses on the development of subunit vaccines protecting against bacterial diseases. Our past research allowed for the identification of OmpC epitope, exposed one the Shigella surface. This fragment interacts very strongly with antibodies present in human blood and is an ideal antigen for immunization, inducing natural protection without the risk of autoimmunity. Currently we are developing vaccine prototype based on the immunogenic peptides representing the epitope sequence. Based on in vitro studies we are evaluating toxicity and safety of vaccine prototype. In addition, we are investigating the mechanism of action of a vaccine prototype using proteomics and in vitro cell line model stimulated with the vaccine. As a result of the project, we will obtain a vaccine prototype with its formulation in an adjuvant.

  • Meltome Atlas development

In recent years, I have become increasingly interested in the effects of heat on living organisms. As a trained microbiologist I am particularly interested if there is any connection between the effect of heat treatment (external hyperthermia) and fever, which leads to body temperature elevation in case of infection. In particular, our group wants to explore how temperature leads to bacterial protein denaturation and which of the proteins denature at first at the range of infectious fever. It is known that fever has an impact over diverse types of pathogens, including bacteria, viruses, and parasites. Although many effects of fever over the human immune system is described elsewhere, the impact of heat release during fever on the bacterial cells has not been broadly investigated. Due to those reasons we want to determine the group of bacterial proteins, which denature in temperatures between 37-43 °C, the scope of fever and the temperature reached at inflammation site in humans. Our studies will allow to assess if pathogen growth inhibition might be affected by fever and lead to thermal denaturation of the bacterial proteins which are associated with replication, transcription or other processes responsible for bacteria surveillance. To understand the impact of heat treatment on bacterial cells we use mass spectrometry-based proteomics and TPP-R workflow. In addition, we are assessing the influence of heat-weakened bacteria on the development of immune response by measuring the response of human cells to the treatment with pre-heated bacteria.

 

Project group members:

Anna Jarząb, PhD (anna.jarzab@hirszfeld.pl)

Karina Krasna (karina.krasna@hirszfeld.pl)

Eva Krzyżewska-Dudek, PhD (eva.krzyzewska@hirszfeld.pl)

Bernadeta Szostko (bernadeta.szostko@hirszfeld.pl)

 

Publications:

  • Torlot L, Jarzab A, Albert J, Pók-Udvari A, Stahler A, Holch J, Peilstöcker D, Heinemann V, Kirchner T, Kumbrink J, Küster B, Jung A: Proteomics uncover EPHA2 as a potential novel therapeutic target in colorectal cancer cell lines with acquired cetuximab resistance. J Cancer Res Clin Oncol 2023 Feb;149(2):669-682
  • Wojciechowska A, Bregier Jarzębowska R, Komarnicka UK, Kozieł S, Szuster Ciesielska A, Sztandera Tymoczek M, Jarząb A, Staszak Z, Witkowska D, Bojarska Junak A, Julia Jezierska: Isothiocyanate l-argininato copper(II) complexes – Solution structure, DNA interaction, anticancer and antimicrobial activity Chem Biol Interact.2021 Oct 1;348:109636
  • Selkrig J, Stanifer M, Mateus A, Mitosch K, Barrio-Hernandez I, Rettel M, Kim H, Voogdt CGP, Walch P, Kee C, Kurzawa N, Stein F, Potel C,Jarzab A, Kuster B, Bartenschlager R, Boulant S, Beltrao P, Typas A, Savitski MM: SARS-CoV-2 infection remodels the host protein thermal stability landscape. Mol Syst Biol.2021 Feb;17(2):e10188
  • Jarzab A, Kurzawa N, Hopf T, Moerch M, Zecha J, Leijten N, Musiol E, Maschberger M, Stoehr G , Daly C, Samaras P, Mergner J, Spanier B, Angelov A, Werner T, Bantscheff M, Wilhelm M, Klingenspor M, Lemeer S, Liebl W, Hahne H, Savitski MM, Kuster B: Meltome Atlas – thermal proteome stability across the tree of life. Nature Methods 2020 May 17(5):495-503
  • Wojciechowska A, Szuster-Ciesielska A, Sztandera M, Bregier-Jarzębowska R,Jarząb A, Rojek T, Komarnicka UK, Bojarska-Junak A, Jezierska J: L‐argininato copper(II) complexes in solution exert significant selective anticancer and antimicrobial activities. Applied Organometallic Chemistry. 2020 Aug 34(8)
  • Samaras P, Schmidt T, Frejno M, Gessulat S, Reinecke M, Jarzab A, Zecha J, Mergner J, Giansanti P, Ehrlich HC, Aiche S, Rank J, Kienegger H, Krcmar H, Kuster B, Wilhelm M: ProteomicsDB: a multi-omicsand multi-organism resource for life science research. Nucleic Acids Res. 2019 Oct 30
  • Rechenberger J, Samaras P, Jarzab A, Behr J, Frejno M, Djukovic A, Sanz J, González-Barberá EM, Salavert M, López-Hontangas JL, Xavier KB, Debrauwer L, Rolain JM, Sanz M, Garcia-Garcera M, Wilhelm M, Ubeda C, Kuster B. Challenges in Clinical Metaproteomics Highlighted by the Analysis of Acute Leukemia Patients with Gut Colonization by Multidrug-Resistant Enterobacteriaceae. Proteomes. 2019 Jan 8;7(1):2
  • Jarzab A, Witkowska D, Ziomek E, Setner B, Czajkowska A, Dorot M, Szewczuk Z, Gamian A: Cyclic OmpC peptidic epitope conjugated to tetanus toxoid as a potential vaccine candidate against shigellosis. Vaccine. 2018 Jul 25;36(31):4641-4649
  • Frejno M, Zenezini Chiozzi R, Wilhelm M, Koch H, Zheng R, Klaeger S, Ruprecht B, Meng C, Kramer K, Jarzab A, Heinzlmeir S, Johnstone E, Domingo E, Kerr D, Jesinghaus M, Slotta-Huspenina J, Weichert W, Knapp S, Feller SM, Kuster B. Pharmacoproteomic haracterization of human colon and rectal cancer. Mol Syst Biol. 2017 Nov 3;13(11):951
  • Grzymajlo K, Ugorski M, Suchanski J, Kedzierska AE, Kolenda R, Jarzab A, Biernatowska A, Schierack P: The Novel Type 1 Fimbriae FimH Receptor Calreticulin Plays a Role in Salmonella Host Specificity. Front Cell Infect Microbiol. 2017 Jul 19;7:326
  • Bawiec A, Paweska K, Jarzab A.: Changes in the microbial composition of municipal wastewater treated in biological processes. Journal of Ecological Engineering (2016) 17(3):41-46
  • Kałuża A, Jarzab A, Gamian A, Kratz EM, Zimmer M, Ferens-Sieczkowska M: Preliminary MALDI-TOF-MS analysis of seminal plasma N-glycome of infertile men. Carbohydr Res. 2016 Nov 29;435:19-25
  • Olejnik B, Jarzab A, Kratz EM, Zimmer M, Gamian A, Ferens-Sieczkowska M: Terminal mannose residues in seminal plasma glycoproteins of infertile men. Int. J Mol. Sci.; 2015 Jul 2;16(7):14933-50
  • Wojciechowska A, Gągor A, Zierkiewicz W, Jarzab A, Dylong A, Zierkiewicz W: Metal-organic framework in L-argininato coper(II) ions polymer – structure, spectroscopic properties, theoretical studies and microbiological activity. RSC Adv., 2015, 5, 36295-36306
  • Smolarek D, Hattab C, Buczkowska A, Kaczmarek R, Jarzab A, Cochet S, de Brevern AG, Lukasiewicz J, Jachymek W, Niedziela T, Grodecka M, Wasniowska K, Colin Aronovicz Y, Bertrand O, Czerwinski M: Studies of a murine monoclonal antibody directed against DARC: reappraisal of its specificity. PloS One, 2015;10(2):e0116472
  • Jarzab A, Witkowska D, Ziomek E, Dąbrowska A, Szewczuk Z, Gamian A: Shigella flexneri 3a outer membrane protein C epitope recognized by human umbilical cord sera and associated with protective activity. PloS One, 2013; 8(8): e70539
  • Jarzab A, Skowicki M, Witkowska D: Subunits vaccines – antigens, carriers, conjugation methods and the role of adjuvants. Post. Hig. Med. Dosw. 2013; 67: 1128-1143
  • Lis J, Jarzab A, Witkowska D: Molecular mimicry in the etiology of autoimmune diseases. Post. Hig. Med. Dosw., 2012, 66, 505-524
  • Jarzab A, Witkowska D, Szostko B, Hirnle L, Gamian A: Potential carrier or antigen for conjugate vaccine: OMP-38 from Flexneri 3a – isolation and purification strategies. Sepsis, 2011; 1(4):39-45
  • Jarzab A, Górska-Frączek S, Rybka J, Witkowska D: Enterobacteriaceae infection – diagnosis, antibiotic resistance and prevention. Post. Hig. Med. Dosw., 2011; 65, 55-72
  • Górska S, Jarzab A, Gamian A: Probiotic bacteria in the human gastrointestinal tract as a factor stimulating the immune system. Hig. Med. Dosw., 2009; 63, 653-667

 

Patents:

  • International patent: WO2014/073998A1, 15.05.2014; Polish patent: PL220297B1, 30.10.2015 and USA patent: US9890194B2, 13.02.2018 „Epitope and its use”
  • International patent: WO2016/012951A1, 28.01.2016 and Polish patent: PL235826B1, 02.11.2020 „Immunogenic conjugate and its use in the prophylaxis and treatment of infections caused by Enterobacteriaceae”
  • Polish patent: PL407772A1, 22.04.2014 „Crystalline form of the complex chloride trihydrate [copper (II)di (2-amino-5-guanidynopenthano) (4,4 ‘-dipirydyl)] and a method for its preparation”
  • Polish patent: PL227111B1, 31.10.2017„Crystalline form of the complex of [(2-amino-5-guanidynopenthane)di(thiocyanate)] copper (II) and method for producing it”
  • Polish patent: PL408663B1, 31.08.2015 „Crystalline form of the chloride trihydrate complex of [(2-amino-5-guanidyno-penthane)chloro(2,2’-dipyridyle) copper (II)] and method for producing it”

 

Member of scientific societies:

since 2013          Mentor in TopMinds of Top500 Innovators and Fulbright Society initiative, Warsaw, Poland

since 2024          Member of the Polish Proteomics Society, Poznan, Poland

since 2013          Member of the Top500 Innovators Association, Warsaw, Poland

since 2015          Member of the Alexander von Humboldt Network, Bonn and the national division of AvH Association, Cracow

2017 – 20            Member of the Human Proteome Organization, Vancouver, BC, Canada

2008 – 10            Member of The International Association for the Exchange of Students for Technical Experience (IAESTE), Poland

 

Funding:

07.06.2024- 07.06.2029:

Research Grant from National Science Center (NCN) under Sonata Bis 13 Program (2023/50/E/NZ2/00420; 4 740 400 PLN, project PI): Bacterial Meltome Atlas and its use in the assessment of bacterial sensitivity to temperature in the context of infectious fever

1.07.2024- 30.06.2027:

Research Group Linkage Program from Alexander von Humboldt Foundation (55 000 EUR, project PI) Grant for research cooperation between Prof. Dr. Bernhard Küster, Lehrstuhl für Proteomik und Bioanalytik, Technische Universität München and Dr. Anna Jarzab, Institute of Immunology and Experimental Therapy, Polish Academy of Sciences

08.2023-07-2028:

Research Grant from Medical Research Agency under Regional Center for Digitalized Medicine Program (2023/ABM/02/00010, 29 501 115 PLN, proteomics research task PI): Specialized Oncology Center of Digitalized Medicine (OnkoSCMC)

09.2023-09.2024:

Research Grant from National Science Center (NCN) under Miniatura 7 Program (2023/07/X/NZ5/00532; 50 000 PLN, project PI): Antitumor effect of hyperthermia and its potential association with infectious fever

09.2023-09-2026:

Scholarship of the Ministry of Science and Education for outstanding young scientists

03.2023-03-2026:

Research Grant from Leader Program National Center for Research and Development (NCBR): Development of an innovative peptide vaccine protecting against bacterial dysentery (1 500 000 PLN, project PI)

04.2016-01.2021:

Alexander von Humboldt fellowship for postdoctoral researchers: Acquired resistance in colorectal cancer cell line model using proteomics (91 000 EUR, project PI)

2013:

Top 500 Innovators – Science, Management, Commercialization, UC Berkeley, California, USA, Polish Government fellowship

10.2012- 09.2013:

Grant PLUS, Immunochemical characterization of the OMP-38 protein as a potential vaccine candidate (50 000 PLN, project PI)

2011:

Travel fellowship, European Biophysical Societies’ Association (EBSA)

 

Contact:

anna.jarzab@hirszfeld.pl

ORDID: 0000-0002-1059-9147

ResearchGate: https://www.researchgate.net/profile/Anna-Jarzab

Google Scholar: https://scholar.google.com/citations?user=ynUzqxUAAAAJ&hl=pl